Literature DB >> 7646991

Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leucopenia.

M A Haj1, I J Neilly, L A Robbie, G D Adey, B Bennett.   

Abstract

In septic patients caical">pable of normal white cell responses, high plasma levels of pan class="Chemical">PAI-I, t-PA antigen and t-PA-PAI-I complex were observed. The ratios of t-PA and PAI-I were such that free PA activity was almost never observed. In patients severely leucopenic prior to becoming septic the changes were significantly less marked, so presence of leucocytes enhances the fibrinolytic inhibition occurring in sepsis. The non-leucopenic septic group showed greater evidence of thrombin generation in that FPA levels were higher but fibrinogen levels were only slightly less and antithrombin levels not different from those in the leucopenic group. A greater tendency to fibrin deposition and the striking fibrinolytic inhibition noted in patients with normal white cell responses may contribute to the development of some of the complications of sepsis in which fibrin deposition participates and may explain their relative rarity in leucopenic patients. When shock supervened, levels of PAI-I were high in both leucopenic and non-leucopenic groups, indicating that a source of PAI-I outwith the leucocytes themselves contributes to the phenomena observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646991     DOI: 10.1111/j.1365-2141.1995.tb05581.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Cancer patients with septic shock: mortality predictors and neutropenia.

Authors:  Carlos J Regazzoni; Célica Irrazabal; Carlos M Luna; Juan J Poderoso
Journal:  Support Care Cancer       Date:  2004-08-12       Impact factor: 3.603

2.  Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion.

Authors:  Silva Bertuglia; Andrea Giusti
Journal:  BMC Cardiovasc Disord       Date:  2002-06-19       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.